{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T20:18:58Z","timestamp":1773519538958,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.msard.2020.102434","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T12:05:23Z","timestamp":1596629123000},"page":"102434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Idebenone does not inhibit disability progression in primary progressive MS"],"prefix":"10.1016","volume":"45","author":[{"given":"Peter","family":"Kosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianxia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Leinonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruturaj","family":"Masvekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Komori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Wichman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Sandford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0959-9430","authenticated-orcid":false,"given":"Bibiana","family":"Bielekova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.msard.2020.102434_bib0034","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1212\/01.wnl.0000335765.55346.fc","article-title":"Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis","volume":"72","author":"Altmann","year":"2009","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2020.102434_bib0044","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/ana.25083","article-title":"Molecular-based diagnosis of multiple sclerosis and its progressive stage","volume":"82","author":"Barbour","year":"2017","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2020.102434_bib0021","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/1352458516638941","article-title":"The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis","volume":"23","author":"Cadavid","year":"2017","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2020.102434_bib0008","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/WCO.0b013e3283533a25","article-title":"Mitochondrial changes within axons in multiple sclerosis: an update","volume":"25","author":"Campbell","year":"2012","journal-title":"Curr. Opin. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2020.102434_bib0009","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ana.22109","article-title":"Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis","volume":"69","author":"Campbell","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2020.102434_bib0035","doi-asserted-by":"crossref","unstructured":"De Angelis F, Connick P, Parker RA, et\u00a0al. Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. Southampton (UK) 2020.","DOI":"10.3310\/eme07030"},{"issue":"3","key":"10.1016\/j.msard.2020.102434_bib0010","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ana.20736","article-title":"Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients","volume":"59","author":"Dutta","year":"2006","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2020.102434_bib0028","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1212\/WNL.56.3.422","article-title":"European\/Canadian Glatiramer acetate study G. Enhancement frequency decreases with increasing age in relapsing-remitting multiple sclerosis","volume":"56","author":"Filippi","year":"2001","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2020.102434_bib0027","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/135245859900500409","article-title":"The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS society clinical outcomes assessment task force","volume":"5","author":"Fischer","year":"1999","journal-title":"Mult Scler."},{"issue":"10","key":"10.1016\/j.msard.2020.102434_bib0023","first-page":"850","article-title":"Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests","volume":"69","author":"Goodkin","year":"1988","journal-title":"Arch. Phys. Med. Rehabil."},{"issue":"3","key":"10.1016\/j.msard.2020.102434_bib0003","doi-asserted-by":"crossref","first-page":"e17963","DOI":"10.1371\/journal.pone.0017963","article-title":"NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels","volume":"6","author":"Haefeli","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.msard.2020.102434_bib0017","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.4049\/jimmunol.1302884","article-title":"Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases","volume":"192","author":"Han","year":"2014","journal-title":"J. Immunol."},{"issue":"23","key":"10.1016\/j.msard.2020.102434_bib0043","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1523\/JNEUROSCI.1632-17.2020","article-title":"Idebenone has distinct effects on mitochondrial respiration in cortical astrocytes compared to cortical neurons due to differential NQO1 activity","volume":"40","author":"Jaber","year":"2020","journal-title":"J. Neurosci."},{"issue":"Pt 9","key":"10.1016\/j.msard.2020.102434_bib0040","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1093\/brain\/awr170","article-title":"A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy","volume":"134","author":"Klopstock","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.msard.2020.102434_bib0005","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awr170","article-title":"A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy","author":"Klopstock","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.msard.2020.102434_bib0012","first-page":"69","article-title":"Serum GDF15 levels correlate to mitochondrial disease severity and myocardial strain, but Not to disease progression in adult m.3243A>G carriers","volume":"24","author":"Koene","year":"2015","journal-title":"JIMD Rep."},{"issue":"1","key":"10.1016\/j.msard.2020.102434_bib0018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ana.24408","article-title":"Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis","volume":"78","author":"Komori","year":"2015","journal-title":"Annals of neurology"},{"issue":"3","key":"10.1016\/j.msard.2020.102434_bib0002","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/acn3.293","article-title":"Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis","volume":"3","author":"Komori","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2020.102434_bib0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fneur.2016.00131","article-title":"Development of a sensitive outcome for economical drug screening for progressive multiple sclerosis treatment","volume":"7","author":"Kosa","year":"2016","journal-title":"Front. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2020.102434_bib0025","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2020.102434_bib0001","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: pathology and pathogenesis","volume":"8","author":"Lassmann","year":"2012","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2020.102434_bib0032","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple sclerosis pathology","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.msard.2020.102434_bib0039","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12883-016-0564-9","article-title":"Albumin and multiple sclerosis","volume":"16","author":"LeVine","year":"2016","journal-title":"BMC Neurol."},{"issue":"5","key":"10.1016\/j.msard.2020.102434_bib0006","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/brain\/awp046","article-title":"Mitochondrial changes within axons in multiple sclerosis","volume":"132","author":"Mahad","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.msard.2020.102434_bib0041","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.mcn.2012.08.004","article-title":"The optic nerve: a \"mito-window\" on mitochondrial neurodegeneration","volume":"55","author":"Maresca","year":"2013","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.msard.2020.102434_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116616","article-title":"Serum growth differentiation factor 15, but not lactate, is elevated in patients with Parkinson's disease","volume":"409","author":"Miyaue","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.msard.2020.102434_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148709","article-title":"GDF-15 is elevated in children with mitochondrial diseases and is induced by mitochondrial dysfunction","volume":"11","author":"Montero","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2020.102434_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116429","article-title":"GDF-15, a mitochondrial disease biomarker, is associated with the severity of multiple sclerosis","volume":"405","author":"Nohara","year":"2019","journal-title":"J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.msard.2020.102434_bib0036","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1172\/JCI90610","article-title":"Oligodendroglia: metabolic supporters of neurons","volume":"127","author":"Philips","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.msard.2020.102434_bib0019","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria\"","volume":"58","author":"Polman","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2020.102434_bib0014","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.mito.2019.10.005","article-title":"Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy","volume":"50","author":"Poulsen","year":"2020","journal-title":"Mitochondrion"},{"issue":"5","key":"10.1016\/j.msard.2020.102434_bib0022","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1212\/WNL.49.5.1419","article-title":"The measurement of ambulatory impairment in multiple sclerosis","volume":"49","author":"Schwid","year":"1997","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2020.102434_bib0024","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1212\/WNL.34.10.1368","article-title":"A neurologic rating scale (NRS) for use in multiple sclerosis","volume":"34","author":"Sipe","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102434_bib0026","article-title":"Symbol digit modalities test: manual. Loas Angeles","author":"Smith","year":"1982","journal-title":"CA: Western Psychol. Serv."},{"key":"10.1016\/j.msard.2020.102434_bib0037","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-3-7091-0643-3_12","article-title":"Growth\/differentiation factor-15 (GDF-15), a novel member of the TGF-beta superfamily, promotes survival of lesioned mesencephalic dopaminergic neurons in vitro and in vivo and is induced in neurons following cortical lesioning","volume":"65","author":"Strelau","year":"2003","journal-title":"J. Neural Transm. Suppl."},{"issue":"43","key":"10.1016\/j.msard.2020.102434_bib0038","doi-asserted-by":"crossref","first-page":"13640","DOI":"10.1523\/JNEUROSCI.1133-09.2009","article-title":"Progressive postnatal motoneuron loss in mice lacking GDF-15","volume":"29","author":"Strelau","year":"2009","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.msard.2020.102434_bib0004","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0167-4943(89)90011-3","article-title":"Inhibition of brain mitochondrial swelling by idebenone","volume":"8","author":"Suno","year":"1989","journal-title":"Arch. Gerontol. Geriatr."},{"issue":"13","key":"10.1016\/j.msard.2020.102434_bib0033","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1177\/1352458516667568","article-title":"MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study","volume":"22","author":"Tourbah","year":"2016","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.msard.2020.102434_bib0029","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","article-title":"Relapses in multiple sclerosis are age- and time-dependent","volume":"79","author":"Tremlett","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.msard.2020.102434_bib0011","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.freeradbiomed.2006.04.013","article-title":"NAD(P)H:quinone oxidoreductase 1 expression in multiple sclerosis lesions","volume":"41","author":"van Horssen","year":"2006","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.msard.2020.102434_bib0031","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fneur.2017.00577","article-title":"Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments","volume":"8","author":"Weideman","year":"2017","journal-title":"Front. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2020.102434_bib0030","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1212\/WNL.54.9.1734","article-title":"Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, health science Center, and the North American Linomide investigators","volume":"54","author":"Wolinsky","year":"2000","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2020.102434_bib0042","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00401-016-1625-2","article-title":"A neurodegenerative perspective on mitochondrial optic neuropathies","volume":"132","author":"Yu-Wai-Man","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"Pt 7","key":"10.1016\/j.msard.2020.102434_bib0007","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/brain\/awr110","article-title":"Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis","volume":"134","author":"Zambonin","year":"2011","journal-title":"Brain"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:52:43Z","timestamp":1761900763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820305095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":44,"alternative-id":["S2211034820305095"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102434","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Idebenone does not inhibit disability progression in primary progressive MS","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102434","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102434"}}